Oncolytic viruses: perspectives on clinical development

Area of Science:

• Oncology
• Virology
• Drug Development

Background:

• Live anti-cancer agents derived from human pathogens, such as oncolytic viruses (OV), face distinct clinical development hurdles compared to traditional therapies.
• The advancement of OV necessitates addressing challenges beyond standard chemotherapeutics and small molecules.

Purpose of the Study:

• To highlight the critical considerations for the clinical development of oncolytic viruses (OV).
• To emphasize the importance of strategic target selection and managing potential infectious complications in OV therapy.

Main Methods:

• This study reviews the unique challenges in developing live anti-cancer agents, specifically OV.
• It emphasizes the need for careful consideration of preclinical and early clinical data for target selection.
• The review addresses the anticipation of infectious complications for safe and efficient clinical studies.

Main Results:

• Oncolytic virus (OV) development requires meticulous target selection, especially when multiple cancer indications show promise.
• Potential infectious complications associated with OV therapy must be proactively managed for successful clinical trials.
• As more OV progress to clinical stages, these developmental issues gain significance.

Conclusions:

• Successful oncolytic virus (OV) drug development hinges on strategic target selection and robust management of infectious risks.
• Addressing these complexities is vital for the efficient and safe advancement of OV therapies in oncology.
• The increasing clinical presence of OV underscores the growing importance of overcoming these unique developmental challenges.